Sign in

Trial result ·

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/II Clinical Trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This trial tested a new drug, Firsekibart, for gout flares. The drug is given as one shot under the skin. The trial had an early part and a later part. In the early part, people got one dose of 50, 100 or 195 mg. Everyone knew the dose, and doses went up step by step. In the later part, people were put into groups by chance. They got Firsekibart 100 or 195 mg, or a comparison drug called Diprospan. Neither people nor doctors knew who got which drug.

What they found

In total, 120 people got the study drugs. The early part had 29 people, and the later part had 91. In the early part, higher doses eased pain more. The 50 mg dose gave less pain relief than 100 or 195 mg. After 72 hours, pain scores fell in all groups of the later part. With 195 mg, the drop was 5.51 cm. With 100 mg, the drop was 4.72 cm. With Diprospan, the drop was 4.94 cm. The 195 mg dose showed a trend toward more pain relief. The drug was taken up into the blood slowly and cleared slowly. Safety looked good and was alike across doses and Diprospan.

What it means for patients

The authors say one shot of Firsekibart is safe for gout flares. They say people handled the drug well. They report that pain relief grew with the dose. They also think it may lower the risk of flares coming back.

Why it is not certain yet

Only 120 people took part in all. The gain with 195 mg was only a trend, not a clear result. The early part had no comparison group, and everyone knew the dose. The abstract does not show data on flares coming back. The abstract does not say how long people were followed.

Source

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/II Clinical Trial.

PubMed · PMID 42498684

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Gout publications